| Title |
XELOX and bevacizumab followed by single-agent bevacizumab as maintenance therapy as first-line treatment in elderly patients with advanced colorectal cancer: the boxe study
|
|---|---|
| Published in |
Cancer Chemotherapy and Pharmacology, October 2012
|
| DOI | 10.1007/s00280-012-2004-x |
| Pubmed ID | |
| Authors |
Gerardo Rosati, Antonio Avallone, Giuseppe Aprile, Alfredo Butera, Giorgio Reggiardo, Domenico Bilancia |
| Abstract |
The addition of bevacizumab to oxaliplatin-based chemotherapy significantly improved progression-free survival (PFS) in patients with metastatic colorectal cancer (CRC). An increased risk of arterial thromboembolic events has been observed in some trials in older patients, and the potential benefit of a maintenance therapy with bevacizumab alone has not been clearly demonstrated. This phase II study was designed to evaluate the efficacy and safety of XELOX (capecitabine plus oxaliplatin) plus bevacizumab followed by bevacizumab alone in elderly patients with advanced CRC. |
Mendeley readers
The data shown below were compiled from readership statistics for 56 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Spain | 1 | 2% |
| Brazil | 1 | 2% |
| Unknown | 54 | 96% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 7 | 13% |
| Other | 6 | 11% |
| Student > Master | 6 | 11% |
| Student > Bachelor | 5 | 9% |
| Student > Doctoral Student | 4 | 7% |
| Other | 13 | 23% |
| Unknown | 15 | 27% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 28 | 50% |
| Nursing and Health Professions | 4 | 7% |
| Neuroscience | 3 | 5% |
| Agricultural and Biological Sciences | 1 | 2% |
| Computer Science | 1 | 2% |
| Other | 5 | 9% |
| Unknown | 14 | 25% |